Abivax, a biotechnology company, will join the CAC Mid 60 and SBF 120 indices on September 19, 2025, after the Euronext Paris annual review. This move will increase visibility and attract more institutional investors to Abivax’s shares. CEO Marc de Garidel expressed gratitude for the recognition and emphasized their commitment to advancing therapies for chronic inflammatory diseases. Abivax’s lead drug candidate, obefazimod, is currently in Phase 3 clinical trials for ulcerative colitis treatment. For more information, visit www.abivax.com. Contact Abivax Investor Relations at [email protected] or +1 847 987 4878.

Read more at GlobeNewswire: Abivax to Join CAC Mid 60 and SBF 120 Indices Following